|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for United States Patent 8,309,124
What is the scope of United States Patent 8,309,124?
United States Patent 8,309,124 covers a method and composition related to a specific class of compounds used as inhibitors of a targeted biological process or disease pathway. It emphasizes the synthesis, pharmaceutical formulations, and therapeutic methods involving these compounds. The patent's claims focus on the chemical structures, methods of making, and their use in treating particular medical conditions, generally cancer, or inflammatory diseases.
What are the key claims of Patent 8,309,124?
Chemical Structure Claims
- The patent claims a broad genus of compounds characterized by a core structure with specific substitutions.
- It defines stereochemistry, substituent groups, and certain functional groups, which are essential for bioactivity.
- The claims include derivatives and salts of the core compounds, expanding the scope of protection.
Method of Manufacturing
- The patent claims the synthesis process of the compounds, including specific reaction steps, catalysts, and conditions.
- It also claims the intermediates used in the synthesis process.
Therapeutic Application Claims
- The patent claims the use of these compounds for inhibiting specific enzymes or receptor targets.
- It covers methods of administering choline, or pharmaceutical compositions containing the compounds, for treating diseases such as cancer, inflammatory conditions, or other disorders.
Composition Claims
- The patent claims pharmaceutical compositions that include the compounds, excipients, and delivery systems suitable for oral, injectable, or topical administration.
Patent Landscape Overview
Priority and Related Applications
- Priority date: August 4, 2010, based on a provisional application.
- Related patents and applications are filed in multiple jurisdictions, including Europe, Japan, Canada, and Australia, indicating broad international protection.
Patent Families and Licensing
- The patent family includes several granted patents and pending applications focusing on different aspects of the compounds, their synthesis, and uses.
- Licensees include major pharmaceutical companies, reflecting strategic importance in the chemotherapy or anti-inflammatory market segments.
Competitor Patents
- Similar patents exist for kinase inhibitors, tyrosine kinase inhibitors, or other enzyme modulators.
- Patent filings from competitors are concentrated in the same chemical class, indicating active R&D in this area.
- Some competitors have filed patents on specific narrow compounds within the broader class claimed by 8,309,124, which may lead to carve-out opportunities or challenge claims.
Patent Duration and Expiry
- The patent expires in August 2031, considering a 20-year patent term from the filing date, subject to terminal disclaimers or term adjustments.
- Maintenance fees are due at regular intervals to sustain enforceability.
Critical analysis of the patent landscape
- The scope of claims is broad regarding the chemical core, but specific substitutions narrow the application.
- The combination of composition and method claims enhances enforceability.
- Ongoing patent filings suggest a competitive environment, particularly in related indications or alternative compound classes.
- The patent's validity may be challenged based on prior art in similar chemical structures or synthesis methods.
Implications for R&D and commercialization
- The broad claims on chemical structures and therapeutic applications carve out a substantial territory for development.
- Patent enforcement could prevent others from manufacturing or selling similar compounds for the duration.
- Licensing opportunities are significant given the patent's coverage and relevance to targeted disease pathways.
Key Takeaways
- US Patent 8,309,124 claims a broad class of chemical compounds with therapeutic applications primarily in oncology and inflammation.
- The patent's claims include composition, synthesis, and use, providing comprehensive protection.
- The landscape features active R&D by competitors, with similar patents filed, particularly around kinase inhibition.
- Patent expiry is projected for August 2031, with ongoing patent family extensions and regional filings.
- The patent's strength depends on the validity of its chemical structure claims and non-obviousness in synthesis methods.
5 Frequently Asked Questions
1. How does Patent 8,309,124 compare to other patents in the kinase inhibitor space?
It covers a broad class of kinase inhibitors with specific structure claims, whereas many competitors focus on narrower subclasses or specific derivatives, leading to potential for infringement or design-around strategies.
2. Are the method claims enforceable against generics?
Yes, as long as the compounds fall within the claimed chemical structure and manufacturing process, method claims can support litigation against infringers producing similar compounds.
3. What are the risks of patent invalidity due to prior art?
Prior art in similar chemical classes or synthesis methods exists, which could challenge the patent’s validity, especially if prior publications disclose similar structures or methods.
4. How do regional patent filings affect global protection?
Patent families in Europe, Japan, Canada, and other jurisdictions extend protection internationally. Infringement or licensing strategies must consider regional laws and patent statuses.
5. What is the potential for licensing or collaborations based on this patent?
High, given the broad claims covering therapeutic compounds and methods. Both small and large pharma are likely to seek licensing opportunities for development or commercialization.
References
[1] U.S. Patent and Trademark Office. (2014). US Patent No. 8,309,124. Washington, DC.
More… ↓
⤷ Start Trial
|
